"Capecitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.
| Descriptor ID |
D000069287
|
| MeSH Number(s) |
D03.383.742.680.245.500.425 D03.383.742.698.875.404.425 D13.570.230.329.313 D13.570.685.245.500.425
|
| Concept/Terms |
Capecitabine- Capecitabine
- N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
|
Below are MeSH descriptors whose meaning is more general than "Capecitabine".
Below are MeSH descriptors whose meaning is more specific than "Capecitabine".
This graph shows the total number of publications written about "Capecitabine" by people in this website by year, and whether "Capecitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 15 | 15 |
| 2007 | 0 | 9 | 9 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 13 | 13 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 10 | 10 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 8 | 8 |
| 2015 | 1 | 5 | 6 |
| 2016 | 0 | 6 | 6 |
| 2017 | 2 | 5 | 7 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 7 | 10 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 5 | 5 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Capecitabine" by people in Profiles.
-
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist. 2024 Mar 04; 29(3):213-218.
-
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15; 130(10):1747-1757.
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 12; 24(12):1359-1374.
-
National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat. 2024 Jan; 203(2):317-328.
-
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 08; 29(8):2133-2141.
-
Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. Cancer Med. 2023 06; 12(12):13352-13360.
-
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):197-205.
-
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 03 01; 41(7):1359-1369.
-
Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66?years or older. Cancer Med. 2023 02; 12(3):2389-2406.
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.